PT - JOURNAL ARTICLE AU - Jennifer Toller Erausquin AU - Rayner K. J. Tan AU - Maximiliane Uhlich AU - Joel M. Francis AU - Navin Kumar AU - Linda Campbell AU - Wei-Hong Zhang AU - Takhona G. Hlatshwako AU - Priya Kosana AU - Sonam Shah AU - Erica M. Brenner AU - Lore Remmerie AU - Aamirah Mussa AU - Katerina Klapilova AU - Kristen Mark AU - Gabriela Perotta AU - Amanda Gabster AU - Edwin Wouters AU - Sharyn Burns AU - Jacqueline Hendriks AU - Devon J. Hensel AU - Simukai Shamu AU - Jenna Marie Strizzi AU - Tammary Esho AU - Chelsea Morroni AU - Stefano Eleuteri AU - Norhafiza Sahril AU - Wah Yun Low AU - Leona Plasilova AU - Gunta Lazdane AU - Michael Marks AU - Adesola Olumide AU - Amr Abdelhamed AU - Alejandra López Gómez AU - Kristien Michielsen AU - Caroline Moreau AU - Joseph D. Tucker AU - I-SHARE research consortium TI - The International Sexual Health And Reproductive Health Survey (I-SHARE-1): A Multi-Country Analysis of Adults from 30 Countries Prior to and During the Initial COVID-19 Wave AID - 10.1101/2021.09.18.21263630 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.18.21263630 4099 - http://medrxiv.org/content/early/2021/10/19/2021.09.18.21263630.short 4100 - http://medrxiv.org/content/early/2021/10/19/2021.09.18.21263630.full AB - Background The COVID-19 pandemic forced billions of people to shelter in place, altering social and sexual relationships worldwide. In many settings, COVID-19 threatened already precarious health services. However, there is limited evidence to date about changes to sexual and reproductive health (SRH) during the initial wave of COVID-19 disease. To address this gap, our team organized a multi-country, cross-sectional online survey as part of a global consortium.Methods Consortium research teams conducted online surveys in 30 countries. Sampling methods included convenience, online panels, and population-representative. Primary outcomes included sexual behaviors, partner violence, and SRH service utilization, and we compared three months prior to and three months after policy measures to mitigate COVID-19. We used established indicators and analyses pre-specified in our protocol. We conducted meta-analyses for primary outcomes and graded the certainty of the evidence using Cochrane methods. Descriptive analyses included 22,724 individuals in 25 countries. Five additional countries with sample sizes <200 were included in descriptive meta-analyses.Results Respondents were mean age 34 years; most identified as women (15160; 66.7%), cis-gender (19432; 86.6%) and heterosexual (16592; 77.9%). Among 4546 respondents with casual partners, condom use stayed the same for 3374 (74.4%) people and 640 (14.1%) people reported a decline. Fewer respondents reported physical or sexual partner violence during COVID-19 measures (1063/15144, 7.0%) compared to the period before COVID-19 measures (1469/15887, 9.3%). COVID-19 measures impeded access to condoms (933/10790, 8.7%), contraceptives (610/8175, 7.5%), and HIV/STI testing (750/1965, 30.7%). Pooled estimates from meta-analysis indicate during COVID-19 measures, 32.3% (95% CI 23.9-42.1) of people needing HIV/STI testing had hindered access, 4.4% (95% CI 3.4-5.4) experienced partner violence, and 5.8% (95% CI 5.4-8.2) decreased casual partner condom use (moderate certainty of evidence for each outcome). Meta-analysis findings were robust in sensitivity analyses that examined country income level, sample size, and sampling strategy.Conclusion Open science methods are feasible to organize research studies as part of emergency responses. The initial COVID-19 wave impacted SRH behaviors and access to services across diverse global settings.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols http://dx.doi.org/10.1136/sextrans-2020-054664 Funding StatementThis research was supported by the NIH (UG3HD096929 and NIAID K24AI143471). In Latvia, this research was supported by the National Research Programme to Lessen the Effects of COVID-19 (VPP-COVID-2020/1-0011).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Ghent Ethics Committee evaluated the multi-country analysis on 28 July 2020 and approved the study (BUNB67020000378). Our consortium required individual ethical approval from each of the participating research teams. Individual ethical committee approval letters are available upon request.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSharing of data for multi-country comparisons is governed by data sharing agreements. Data can only be shared within the I-SHARE research consortium. In-country leads maintain control of individual country data and decisions about country-level data access are made solely by them.